Literature DB >> 21126917

Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study.

Marie-Laurence Lambert1, Carl Suetens, Anne Savey, Mercedes Palomar, Michael Hiesmayr, Ingrid Morales, Antonella Agodi, Uwe Frank, Karl Mertens, Martin Schumacher, Martin Wolkewitz.   

Abstract

BACKGROUND: Patients admitted to intensive-care units are at high risk of health-care-associated infections, and many are caused by antimicrobial-resistant pathogens. We aimed to assess excess mortality and length of stay in intensive-care units from bloodstream infections and pneumonia.
METHODS: We analysed data collected prospectively from intensive-care units that reported according to the European standard protocol for surveillance of health-care-associated infections. We focused on the most frequent causative microorganisms. Resistance was defined as resistance to ceftazidime (Acinetobacter baumannii or Pseudomonas aeruginosa), third-generation cephalosporins (Escherichia coli), and oxacillin (Staphylococcus aureus). We defined 20 different exposures according to infection site, microorganism, and resistance status. For every exposure, we compared outcomes between patients exposed and unexposed by use of time-dependent regression modelling. We adjusted results for patients' characteristics and time-dependency of the exposure.
FINDINGS: We obtained data for 119 699 patients who were admitted for more than 2 days to 537 intensive-care units in ten countries between Jan 1, 2005, and Dec 31, 2008. Excess risk of death (hazard ratio) for pneumonia in the fully adjusted model ranged from 1·7 (95% CI 1·4-1·9) for drug-sensitive S aureus to 3·5 (2·9-4·2) for drug-resistant P aeruginosa. For bloodstream infections, the excess risk ranged from 2·1 (1·6-2·6) for drug-sensitive S aureus to 4·0 (2·7-5·8) for drug-resistant P aeruginosa. Risk of death associated with antimicrobial resistance (ie, additional risk of death to that of the infection) was 1·2 (1·1-1·4) for pneumonia and 1·2 (0·9-1·5) for bloodstream infections for a combination of all four microorganisms, and was highest for S aureus (pneumonia 1·3 [1·0-1·6], bloodstream infections 1·6 [1·1-2·3]). Antimicrobial resistance did not significantly increase length of stay; the hazard ratio for discharge, dead or alive, for sensitive microorganisms compared with resistant microorganisms (all four combined) was 1·05 (0·97-1·13) for pneumonia and 1·02 (0·98-1·17) for bloodstream infections. P aeruginosa had the highest burden of health-care-acquired infections because of its high prevalence and pathogenicity of both its drug-sensitive and drug-resistant strains.
INTERPRETATION: Health-care-associated bloodstream infections and pneumonia greatly increase mortality and pneumonia increase length of stay in intensive-care units; the additional effect of the most common antimicrobial resistance patterns is comparatively low. FUNDING: European Commission (DG Sanco).
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21126917     DOI: 10.1016/S1473-3099(10)70258-9

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  94 in total

1.  Editorial commentary: Asking the right questions: morbidity, mortality, and measuring what's important in unbiased evaluations of antimicrobials.

Authors:  John H Powers
Journal:  Clin Infect Dis       Date:  2012-03-30       Impact factor: 9.079

2.  Differential responses of human dendritic cells to metabolites from the oral/airway microbiome.

Authors:  K Whiteson; S Agrawal; A Agrawal
Journal:  Clin Exp Immunol       Date:  2017-03-21       Impact factor: 4.330

3.  A Cautionary Tale on the Central Venous Catheter: Medical Note for Oral Physicians.

Authors:  Ramasamy Chidambaram
Journal:  Malays J Med Sci       Date:  2015-09

4.  Newly Named Klebsiella aerogenes (formerly Enterobacter aerogenes) Is Associated with Poor Clinical Outcomes Relative to Other Enterobacter Species in Patients with Bloodstream Infection.

Authors:  Austin Wesevich; Granger Sutton; Felicia Ruffin; Lawrence P Park; Derrick E Fouts; Vance G Fowler; Joshua T Thaden
Journal:  J Clin Microbiol       Date:  2020-08-24       Impact factor: 5.948

5.  Impact of daily bathing with chlorhexidine gluconate on ventilator associated pneumonia in intensive care units: a meta-analysis.

Authors:  Wensen Chen; Quan Cao; Songqin Li; Huifen Li; Weihong Zhang
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

6.  Clinical relevance of bacterial resistance in lower respiratory tract infection in primary care: secondary analysis of a multicentre European trial.

Authors:  Jolien Teepe; Berna Dl Broekhuizen; Herman Goossens; Patricia Marinka Hordijk; Katherine Loens; Christine Lammens; Margareta Ieven; Paul Little; Chris C Butler; Samuel Coenen; Maciek Godycki-Cwirko; Birgitta Henriques-Normark; Theo Jm Verheij
Journal:  Br J Gen Pract       Date:  2018-07-30       Impact factor: 5.386

7.  Non-directed bronchial lavage is a safe method for sampling the respiratory tract in critically ill patient.

Authors:  B V Bonvento; J A Rooney; M O Columb; B A McGrath; A M Bentley; T W Felton
Journal:  J Intensive Care Soc       Date:  2018-11-13

8.  Discordant minimum inhibitory concentration analysis: a new path to licensure for anti-infective drugs.

Authors:  Dean Follmann; Erica Brittain; John H Powers
Journal:  Clin Trials       Date:  2013       Impact factor: 2.486

9.  Lichen secondary metabolite evernic acid as potential quorum sensing inhibitor against Pseudomonas aeruginosa.

Authors:  Barış Gökalsın; Nüzhet Cenk Sesal
Journal:  World J Microbiol Biotechnol       Date:  2016-07-27       Impact factor: 3.312

10.  Comparison of severe healthcare-associated pneumonia with severe community-acquired pneumonia.

Authors:  Byeong-Ho Jeong; Eun Ju Jeon; Hongseok Yoo; Won-Jung Koh; Gee Young Suh; Man Pyo Chung; O Jung Kwon; Kyeongman Jeon
Journal:  Lung       Date:  2013-12-01       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.